XTL Biopharmaceuticals Ltd. XTLB
Annual
Quarterly
FY2024 · ended Dec 31, 2024 · Revenue $451,000 · Filed Apr 30, 2025
XTL Biopharmaceuticals Ltd. (XTLB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $451,000 and a net loss of $1.0 million. Free cash flow was -$1.7 million. As of Dec 31, 2024 it held $371,000 in cash and investments and $276,000 in total debt.
Revenue
$451,000
Net income
$-1.03M
+23.8% vs prior year
Operating cash flow
$-1.62M
-79.6% vs prior year
Free cash flow
$-1.67M
-96.5% vs prior year
EPS
$-0.00
-50.0% vs prior year
Dividend per share
None
Shares outstanding
946.24M
+7.4% vs prior year
Net cash
$95,000
FY 2024
Operating margin
-481.6%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XTLB (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1023549
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $451,000 | — | — | — | — |
| Operating income | -$2.2M | -$880,000 | -$1.0M | -$948,000 | -$842,000 |
| Net income | -$1.0M | -$1.3M | $435,000 | -$3.0M | -$763,000 |
| Diluted EPS | -$0.00 | -$0.00 | $0.00 | — | — |
| Operating cash flow | -$1.6M | -$901,000 | -$1.0M | -$850,000 | -$908,000 |
| Free cash flow | -$1.7M | — | — | -$851,000 | -$910,000 |
| Total assets | $8.6M | $4.2M | $6.6M | $6.5M | $7.2M |
| Stockholders' equity | $5.4M | $4.0M | $5.3M | $3.6M | $6.5M |
| Cash and investments | $371,000 | $2.1M | $3.0M | $6.0M | $4.5M |
| Total debt | $276,000 | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 14, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Aug 5, 2026 | Aug 5, 2026 |
| 6-K | Current report (foreign issuer) | Jul 21, 2026 | Jul 21, 2026 |
| 20-F | Annual report (foreign issuer) | Jun 30, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Jun 30, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jun 29, 2026 | Jun 29, 2026 |
All 546 XTL Biopharmaceuticals Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.